De novo metastatic castration sensitive prostate cancer (mCSPC) accounts for about 4% of all prostate tumors in Western Countries. This condition has a heterogeneous biological e clinical behavior, ranging from indolent to aggressive and rapidly fatal forms. Recently, the therapeutic landscape for mCSPC has been broadly enriched; indeed robust evidence supports the addiction of chemotherapy (docetaxel) or abiraterone acetate to androgen deprivation therapy (ADT), the latter considered for long the unique standard of care. However, the prognostic stratification and the definition of the ideal therapeutic approach for the subpopulation of de novo mCSPC - albeit largely represented in pivotal clinical trials enrolling mCSPC patients - have yet to be prospectively outlined. The aim of this review was to describe the current state of art about clinical presentation, prognostic classification, and different therapeutic options available for de novo mCSPC patients. Furthermore, we shed light on ongoing clinical trials and future perspectives for this disease setting.
Cancer treatment reviews. 2018 Aug 11 [Epub]
Claudia Mosillo, Roberto Iacovelli, Chiara Ciccarese, Emanuela Fantinel, Davide Bimbatti, Matteo Brunelli, Iolanda Bisogno, Stefania Kinspergher, Consuelo Buttigliero, Marcello Tucci, Orazio Caffo, Giampaolo Tortora
Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; Department of Radiological, Oncological, and Pathological Sciences, University "Sapienza" of Rome, Roma, Italy., Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: ., Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy., Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy., Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy., Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy; U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.